EYPT biotech catalysts & pipeline

EYEPOINT INC · Data as of 2026-10-25

Upcoming catalysts

DURAVYU (vorolanib intravitreal insert) — FDA meeting

Q4 2026

1 Pre-NDA meeting in Q4 2026 based on totality of data

DURAVYU (vorolanib intravitreal insert) — NDA/BLA submission

H1 2027

our expectations regarding our clinical development and regulatory plans, including the submission of a potential FDA New Drug Application for DURAVYU™ for the potential treatment of wet AMD in the first half of 2027;

Source filing

DURAVYU (vorolanib intravitreal insert) — Topline data

Q4 2027

The Company continues to advance the ongoing pivotal COMO and CAPRI clinical trials, with topline data expected in the fourth quarter of 2027.

Source filing

Explore the free biotech catalyst calendar